Diagnostic and Therapeutic Uses

A Pathogen Signature in Breast Cancer

Abnormal bacterial changes in breast tissue in a healthy woman may increase the risk and development of breast cancer. Similar evidence suggests that the same is also true for other cancers. Basal-like breast cancers, the majority of which are “triple negative,” make up 10-20% of all breast cancers. Sadly, women diagnosed with this type of breast cancer have a poorer prognosis when compared to those diagnosed with other kinds of breast cancer. This is due to the lack of targeted therapies for these tumors.

ExcaliVir has made important scientific discoveries regarding the microbial signature of triple negative breast cancer. These discoveries have the potential for creating a new frontier in the detection, monitoring, therapeutic selection and management of breast cancer.

Aid in Diagnosis

37 million mammograms are performed each year, and 3/4 of women who have positive mammograms will test negative after biopsies. Of the 1.6 million women per year that have breast biopsies only about 20% test positive for cancer. The false positive rate is too high.

Pathochip may provide additional information to diagnose patients more efficiently, reducing needless biopsies, patient fear and anxiety, while saving health care costs.

Aid in Medical Management

The microbiome affects the metabolism of pharmaceutical agents including those used to treat cancer. Breast cancer tumors have high heterogeneity with different prognosis and response to therapies depending on subgroup.

PathoChip provides information on the patient’s tumor microbiome and comparing this to the unique microbiome signatures associated with triple negative breast cancer and other types of breast cancer. This information may improve therapeutic choices, dosing regimens, monitoring strategies, and use of antibiotics.

Potential Future Applications

Other cancer diagnosis

Food Safety

Industrial Applications

Bioterrorism monitoring

Clinical Diagnosis

PathoChip At Work

Recently, a hospital patient with acute myelogenous leukemia was seriously ill due to an unknown pathogen, and not responding to treatments. Paralysis was setting in, but none of the usual diagnostic tests could identify the causative pathogen. PathoChip was used and in a single screen tested for all known viruses and human pathogenic bacteria, fungi, protozoa and helminths! Within 24 hours the Pathochip platform identified a rare fungus and appropriate treatment was prescribed successfully resolving the patient’s condition.